Tag: CHM

Health Care

Chiye Organic Silicon Material (Shanghai) Co., Ltd Invests USD1.6 Million on Production Plant

admin

SHANGHAI, March 18, 2015 /PRNewswire/ — Chiye Organic Silicon Material (Shanghai) Co., Ltd, a leading manufacturer and supplier of organic silicon, announced today that it has launched the investment up to 1.6 million US dollars on a new plant of 3-Isocyanatepropyltriethoxysilane, which is expected to complete and start to work in June 2015. The new plant would be able to supply 500 tons of 3-Isocyanatepropyltriethoxysilane annually to serve the customers in adhesive industry as well as coatings and sealant. It would greatly ease the tight supply of this material in China.

Mr. Chen, the chief operator of Chiye Organic Silicon addressed the importance of technique innovation and he said: “Based on the advanced equipment, the new plant could deal with the hazardous waste sufficiently.” He also believed the new technique could gain greater acceptance of global leading customers. We are confident in our new plant to increase penetration and capture more market share in Europe and America.

About Chiye Organic Silicon Material (Shanghai) Co., Ltd.

Located in Shanghai Pilot Free Trade Zone, Chiye Organic Silicon Material (Shanghai) Co., Ltd is one of the leading manufacturers and suppliers of organic silicon and silicon oil. This also includes Amino Silane, Epoxy Silane, Acryl Silane, Vinyl Silane, Phenyl Silane, Chloro Silane and Alkyl Silane, chemical formula as well as their application solutions, which are widely used in the fields of Building Materials, Glass Fiber, Plastic, Rubber, Coating, Electronics, Cable and Resin etc.

The company distributes products both within China and internationally under the trademark CY, with a product range of more than 40 categories. The Featured Products include:

3-Aminopropyltriethoxysilane (CY-550)
3-(2-Aminoethyl)-aminopropylmethydimethoxysilane (CY-602)
3-(2-Aminoethyl)-aminopropyltrimethoxysilane (CY-792)
3-Mercaptopropyltriethoxysilane (CY-580)
3-Mercaptopropyltrimethoxysilane (CY-590)
3-Glycidoxypropyl-trimethosysilane (CY-560)
3-Methacryloxypropyltrimethoxysilane (CY-570)
Vinyltriethoxysilane (CY-151)
Vinyltrimethoxysilane (CY-171)

The company focuses on the technical innovation and environment safety. 10% revenue was invested in R&D annually and we have enjoyed more than 10 patents of core techniques and products. We have been accredited by many international standard organizations, successively certified by ISO9001-2000 in 2005 and ISO14000 in 2014, which bring in modern management and offer valid guarantee and scientific measures to our staff and facilities. We also work with third parties such as SGS in Europe to obtain accurate, quality information, optimize our research, development and manufacturing process. For more information, please visit our website at: www.chiyechem.com

Chiye Organic Silicon Material (Shanghai) Co., Ltd
Address: Part E1, Floor 4, No. 155, West Fute 1st Road, China (Shanghai) Pilot Free Trade Zone
Attn: Maggie Zhu
E-mail: info@chiyechem.com
Tel: +86-21-58997516
Mobile: +86-13321881626

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/chiye-organic-silicon-material-shanghai-co-ltd-invests-usd16-million-on-production-plant-300049577.html

Health Care

Frost & Sullivan Applauds Neopeutics’ Commitment to Accelerating the Delivery of New Nature-Based Pharmaceuticals and Therapeutics

admin

Neopeutics has shown integrity in partnering with its customers at every stage of the drug discovery process

MOUNTAIN VIEW, Calif., March 3, 2015 /PRNewswire/ — Based on its recent analysis of the enhanced drug discovery market, Frost & Sullivan recognizes Neopeutics, Inc. with the 2015 North America Frost & Sullivan Award for Technology Leadership. Neopeutics has demonstrated a remarkable ability to innovate by offering clients a robust, cost-effective, and easily adaptable set of drug discovery instruments. It uniquely focuses on agents that are catalogued as failing compounds in the early stages of the drug discovery process, enabling customers to lower attrition rates and save drug development costs.

Neopeutics recognized with the 2015 North American Enhanced Drug Discovery Technology Leadership Award

Neopeutics recognized with the 2015 North American Enhanced Drug Discovery Technology Leadership Award

Photo – http://photos.prnasia.com/prnh/20150303/8521501311
Photo – http://photos.prnewswire.com/prnh/20150302/178914

Neopeutics’ contract research activities for regulatory agencies and industry players mainly comprise drug-discovery assistance, data analysis and interpretation, advisory and value-add services, and quality assurance (QA). Therefore, its main products are bioinformatics software, drug screening technology packages, and therapeutic compounds derived from natural resources.

One of the main distinguishing factors of Neopeutics is its dedication to introducing natural herbal products, pharmaceuticals, and therapeutics in the global biopharmaceutical market. It is achieving this through a multi-service drug discovery hub for nature-based therapeutics, which offers a distinct, affordable, high-standard QA/quality control (QC) service. Its end-to-end set of bioinformatics tools and expertise greatly assists the development of flexible, customized software tools such as genomics and proteomics platforms for drug screening and discovery.

Neopeutics’ technology platform has been commercialized not only among large pharmaceutical companies, but also small and medium enterprises, aiding the analysis of nature-based herbal products and nutraceuticals. During the screening phase, bioactive ingredients are extracted, separated, analyzed, and then profiled according to their potential therapeutic action.

“Neopeutics’ technology platform speeds up the identification of new therapeutic candidates by elucidating the mechanisms of action and signaling pathways, followed by the chemical agents in several in silico models,” said Frost & Sullivan Industry Analyst Cecilia Van Cauwenberghe. “Such early screening of compounds helps to guarantee a good safety profile for the agents under study.”

The company’s highly efficient and accurate technology helps determine the behavior of a wide range of compounds with their targets and allows the provision of QA services as a natural extension of its services. Since smaller manufacturers do not possess the facilities, financial resources, or expertise to perform QA, they will benefit greatly from Neopeutics’ techno-marketing. Similarly, it aids government regulatory agencies in establishing the mode of action and safety profiles of herbal medication, which is an important step in the regulatory and approval processes.

“Neopeutics is currently using a first-generation version of its proprietary software package of bioinformatics software tools for the drug screening market, while simultaneously working on launching its second-generation package,” noted Van Cauwenberghe. “It also leverages its bioinformatics capabilities to add value to other in-house, tailor-made solutions and enrich key components. Most of these services are coupled with assessment programs, as well as data analysis and interpretation services.”

Furthermore, the company has strategic advantages in terms of both geography and business development. Its two main locations in the United States and Malaysia are ideal to help it enhance business development activities with the major regional players.

Overall, for its strong integrative strategy and dedication to delivering novel nature-based pharmaceuticals, Neopeutics has been presented with the 2015 Frost & Sullivan Technology Leadership Award.

Each year, Frost & Sullivan presents this award to the company that has demonstrated uniqueness in developing and leveraging new technologies, which significantly impacts both the functionality and the customer value of the new products and applications. The award lauds the high R&D spend toward innovation, its relevance to the industry and the positive impact on brand perception.

Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis and extensive secondary research to identify best practices in the industry.

About Neopeutics, Inc.

Neopeutics is an early stage drug discovery contract research partner that offers our partners and clients a robust and cost effective set of pre-clinical drug discovery tools. Our proprietary ChemoMAP® technology package is perfectly suited for “failing” compounds in the early stages of drug discovery, thereby helping to achieve notable savings in drug development costs. In addition, our discovery platform can also help our clients enhance the accuracy and speed of their “hit” identification process as well as elucidate the mode of action and confirm the efficacy and safety of their in-development and on-the-market products, thereby helping to improve drug safety and build consumer confidence.

As systems biology opens up limitless possibilities in drug discovery, we invite you to explore the horizon of drug discovery with us.

For more information, please visit www.neopeutics.com, or contact us at info@neopeutics.com.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants.

Our “Growth Partnership” supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
  • The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us: Start the discussion
Join Us: Join our community
Subscribe: Newsletter on “the next big thing”
Register: Gain access to visionary innovation

Contact:
Mireya Espinoza
P: +1.210. 247.3870
F: +1.210.348.1003
E: mireya.espinoza@frost.com

Health Care

AMRI Realigns Global Operations to Enhance Continuous Supply Chain for Customers

admin

— Announces Key Leadership Promotions

ALBANY, N.Y., Feb. 13, 2015 /PRNewswire/ — AMRI (NASDAQ: AMRI) today announced that it has implemented several changes to further optimize global business operations in order to enhance continuity from early development through to commercial supply and accelerate the company’s global growth objectives.

The realigned structure will continue to improve performance and reliability by maximizing the value of AMRI’s various integrated services for customers. Enhancing the link between operations and core business segments, together with the corporate-level support functions, will foster real-time decision making, appropriate resource prioritization and integration necessary to create a more adaptive, efficient and customer-centric global pharmaceutical services company.

Steven R. Hagen, Ph.D., Senior Vice President of Manufacturing and Pharmaceuticals, has assumed oversight of AMRI’s global operations infrastructure ensuring that the manufacturing and development operations execute efficiently, safely and to AMRI’s quality standards. With this change, AMRI has improved line-of-sight of all global operations across all of its service offerings and all of its locations.

George Svokos, Senior Vice President Sales and General Manager-API, has assumed responsibility for a newly created Commercial function as Chief Commercial Officer, which comprises Sales and Marketing, Project Management and Supply Chain under one roof. In addition to leading the Commercial function, Mr. Svokos will continue to spearhead AMRI’s integrated API Manufacturing offering that includes Chemical Development and Large Scale API Manufacturing.

William S. Marth, AMRI’s president and chief executive officer, said, “We are committed to continually improving our business operations, and are confident that streamlining our global operations will further enhance our ability to provide customers with a fluid, continuous supply chain across all of our businesses. In addition, the optimization and globalization of customer relations and project management strengthens our ability to manage the customer interface.”

In tandem with the realignment, AMRI also announced the following senior management promotions:

Milton Boyer was promoted to Senior Vice President of Drug Product Manufacturing, from his former role as VP of Parenterals. Mr. Boyer’s expertise from OsoBio will be applied across all phases of Drug Product, which spans from Pre-Formulation and Formulation Development all the way through to Late Phase and Commercial Parenteral Manufacturing.

Christopher Conway was promoted to Senior Vice President of Global Sales and Marketing, and is responsible for all global sales, marketing and customer operations functions. Mr. Conway, who joined AMRI in 2008, was most recently Vice President of Global Sales and Marketing. Before joining AMRI, Mr. Conway held sales and leadership positions of increasing responsibility at Johnson and Johnson.

To effectively support the growing interface between Chemical Development and API and best align AMRI’s resources to effectively manage and transition customer projects, Rajesh Shenoy, Ph.D., was promoted to Senior Director of Global Chemical Development. Dr. Shenoy has been with AMRI since 1998 in various roles of increasing responsibility. Most recently, Dr. Shenoy was Senior Director of Global Project Management. Dr. Shenoy earned a Ph.D. in Organic Chemistry at the University of Akron and conducted postdoctoral research at Kent State University.

About AMRI
Albany Molecular Research Inc. (AMRI) is a global contract research and manufacturing organization that has been working with the Life Sciences industry to improve patient outcomes and the quality of life for more than two decades. With locations in North America, Europe and Asia, our key business segments include Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API) and Drug Product Manufacturing. Our DDS segment provides comprehensive services from hit identification to IND, including expertise with diverse chemistry, library design and synthesis, in vitro biology and pharmacology, drug metabolism and pharmacokinetics, as well as natural products. API Manufacturing supports the chemical development and cGMP manufacture of complex API, including potent, controlled substances, biologics, peptides, steroids and cytotoxic compounds. Drug Product Manufacturing supports drug product development through commercial scale production of complex liquid-filled and lyophilized parenteral formulations. For more information about AMRI, please visit our website at www.amriglobal.com or follow us on Twitter (@amriglobal).

Health Care

AMRI Hires Chief Information Officer

admin

ALBANY, New York, Feb. 10, 2015 /PRNewswire/ — AMRI (NASDAQ: AMRI) announced today that Jimmy Wang, Ph.D., fills the newly created position of Chief Information Officer, effective immediately. He replaces Carl Neumann, Senior Director, Information Technology, who retires this month.

In this role, Dr. Wang will manage and oversee major technology initiatives at AMRI, as well as the day-to-day Information Technology operations. Among his responsibilities will be to implement scalable and agile information technology solutions that align with AMRI’s growth objectives and global operations.

“We are pleased to welcome Jimmy to the AMRI team,” said William S. Marth, president and chief executive officer, AMRI. “As an award-winning industry professional with a proven track record in delivering complex IT transformations, we look forward to leveraging his strategic direction to create a scalable IT infrastructure that will accommodate growth. We appreciate Carl’s many years of dedication and service with AMRI, and wish him the best in his retirement.”

Dr. Wang brings 25 years of experience managing and deploying technology innovations to various technology, telecommunications and global pharmaceutical companies. Most recently he served as Senior Vice President and Chief Information Officer at OPKO Health Inc., where he established the company’s global IT governance process and transformed IT into a centralized delivery organization. Before OPKO Health, Dr. Wang was Senior Vice President and Chief Information Officer at Vertex Pharmaceuticals Inc., where he played a major role in managing implementation, consolidation, and support of Enterprise Operations Support Systems, as well as led the area of scientific computing to use technology to support the area of Innovation and Research. Before Vertex, Dr. Wang was at Teva Pharmaceuticals-America, where he was Vice President and Chief Information Officer. Dr. Wang received his Ph.D. in Operations Research from Southern Methodist University in 1990.

About AMRI
Albany Molecular Research Inc. (AMRI) is a global contract research and manufacturing organization that has been working with the Life Sciences industry to improve patient outcomes and the quality of life for more than two decades. With locations in North America, Europe and Asia, our key business segments include Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), and Drug Product Manufacturing. Our DDS segment provides comprehensive services from hit identification to IND, including expertise with diverse chemistry, library design and synthesis, in vitro biology and pharmacology, drug metabolism and pharmacokinetics, as well as natural products. API Manufacturing supports the chemical development and cGMP manufacture of complex API, including potent, controlled substances, biologics, peptides, steroids, and cytotoxic compounds. Drug Product Manufacturing supports drug product development through commercial scale production of complex liquid-filled and lyophilized parenteral formulations. For more information about AMRI, please visit our website at www.amriglobal.com or follow us on Twitter (@amriglobal).

Health Care

Elementis Specialties’ Personal Care Business Achieves Certification in Good Manufacturing Practice

admin

LONDON, Jan. 20, 2015 /PRNewswire/ — Elementis Specialties is proud to announce its Livingston, Scotland, manufacturing site has completed European Federation for Cosmetic Ingredients (EFfCI) certification for Good Manufacturing Practice (2012) for Bentone Gel products. The Livingston, Scotland, site is the primary manufacturing site for the Personal Care Business Unit and supplies naturally derived based rheology modifiers for color cosmetics and skin care. “In achieving this EFfCI certification we are affirming our commitment to quality, safety and innovation for the personal care industry,” said Luc van Ravenstein, Global Business Unit Director of the Personal Care Business. Elementis Specialties is one of the leading suppliers of raw materials for the cosmetics industry. EFfCI is a European trade association that represents the collective interests of more than 100 manufacturers of chemical and natural ingredients for the cosmetics industry. Adhering to EFfCI GMP Standards for Cosmetics requires a holistic approach to quality assurance, from procurement and through manufacturing processes and distribution channels. Achieving certification requires implementing best practices, maintaining world-class processes and passing a rigorous third-party audit.

About Elementis Specialties Inc. 

Elementis Specialties Inc. provides innovative rheology control additives that are used to enhance the performance of our customers’ products and is part of the Elementis plc group. In 2013, Elementis plc (the “Company”) had annual sales of more than $770 million and employed over 1,300 people worldwide. Elementis operates in more than 30 locations, including 18 manufacturing sites, in 9 countries. Elementis plc has a premium listing on the UK London Stock Exchange and is a member of the FTSE 250 Index, making it one of the 350 largest companies in the UK by market capitalization. As well as being a member of the FTSE4Good Index, Elementis participates in the Ecovadis sustainable supply management programme in which it holds a silver level recognition. Best in class product quality, technical support and customer service are the critical competencies of Elementis Specialties Inc. and provide the platform to deliver value to the coatings, construction, oilfield drilling and personal care markets.

http://www.elementis.com

Health Care

Polymer Chameleons Find New Applications as Research Activities Rise

admin

— Support from governments and universities will help quicken commercialization, finds Frost & Sullivan

MOUNTAIN VIEW, Calif., Jan. 13, 2015 /PRNewswire/ — Polymer chameleons are poised for rapid adoption and commercialization across industries due to their unique attributes and benefits. Despite several challenges, research activities and partnerships between the research community and the industry, as well as funding from both government and private agencies, is helping spearhead development.

Frost & Sullivan

Frost & Sullivan

Logo – http://photos.prnewswire.com/prnh/20150112/168533LOGO

New analysis from Frost & Sullivan, Polymer Chameleons—9 Dimensional Assessment, finds that extensive research studies are underway on the application of polymer chameleons in areas such as drug delivery, molecular separation, flexible chips and biofilms. These technologies will reach commercialization in the next three to four years.

For complimentary access to more information on this research, please visit: http://bit.ly/1BgCdgo.

“Increasing emphasis on smart materials and longer shelf life are driving use of polymer chameleons in various segments, especially healthcare,” said Technical Insights Senior Industry Analyst Aarthi Janakiraman. “The healthcare industry is already researching polymer chameleons in drug delivery products for specialized applications and is looking to expand into other product segments and industries including personal care.”

Customization of polymers according to end-use applications, cost-effective manufacturing and scalability are the most significant challenges faced by technology developers. High raw material cost is another deterrent to large-scale uptake and commercialization.

Nevertheless, research and strategic partnerships are enabling stakeholders to expand the scope of polymer chameleons. The best way for a company to handle an R&D portfolio is to design technologies that are specific to an end application.

“Focus is turning to responsive hydrogels for biomedical applications and protective coatings,” added Technical Insights. “Research studies on polymer chameleons processed from renewable sources are also in progress and will propel polymer chameleons’ development to a commercial scale.”

Polymer Chameleons—9 Dimensional Assessment, a part of the Technical Insights subscription, details the technical capabilities, market needs, and industry requirements of polymer chameleons following extensive interviews with market participants. The study assesses various industry trends and evaluates polymer chameleons through a nine dimensional approach; year of impact, market potential, global footprint, IP activities, funding scenario, breadth of industries, impact on mega trends, potential points of convergence, and size of innovation ecosystem.

Technical Insights is an international technology analysis business that produces a variety of technical news alerts, newsletters, and research services.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants.

Our “Growth Partnership” supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
  • The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us:     Start the discussion

Join Us:           Join our community

Subscribe:       Newsletter on “the next big thing”

Register:         Gain access to visionary innovation

Polymer Chameleons—9 Dimensional Assessment
D55C

Contact:
Ariel Brown
Corporate Communications – North America
P: +1 (210) 247.2481
F: +1 (210) 348.1003
E: ariel.brown@frost.com

http://www.frost.com

Logo – http://photos.prnasia.com/prnh/20150113/8521500202LOGO 

CSE Health Care NET

Diebold, Corning Pioneer World’s First Antimicrobial ATM Touch Screen

admin

NORTH CANTON, Ohio, Jan. 6, 2015 /PRNewswire/ — Diebold, Incorporated (NYSE: DBD) and Corning Incorporated (NYSE: GLW) have teamed up to introduce the first automated teller machine (ATM) touch screen featuring Antimicrobial Corning® Gorilla® Glass. The glass is formulated with an embedded antimicrobial agent, ionic silver, which inhibits the growth of algae, mold, mildew, fungi and bacteria on its surface. The companies will showcase a prototype antimicrobial touch screen on Diebold’s newly released 5500 series ATM in Corning’s booth during the International Consumer Electronics Show (CES), Jan. 6-9, 2015, in Las Vegas.

Logo – http://photos.prnewswire.com/prnh/20080725/DIEBOLDLOGO

“Touched by hundreds of users every day, the ATM is a universal shared touch device,” said Joydeep Lahiri, division vice president and program director, Specialty Surfaces, Corning Incorporated. “Therefore, toughness and antimicrobial protection are desired attributes. For Diebold ATMs, Antimicrobial Corning Gorilla Glass will deliver lifelong antimicrobial activity that won’t compromise toughness or optical clarity.”

Diebold plans to offer Antimicrobial Corning Gorilla Glass as an option on its expanding line of self-service terminals, including the recently launched 5500, 3500, 3700and 9900series ATMs, as well as a retrofit option for existing ATMs.

“Touch screens are found on a growing number of ATMs today. Offering antimicrobial glass on frequently touched surfaces such as the ATM touchscreen will help financial institutions address the concerns of the public,” said Frank A. Natoli, Jr., executive vice president and chief innovation officer, Diebold. “Our innovative collaboration with Corning will help us offer improved durability and antimicrobial function for our next generation of touchscreen ATMs.”

Antimicrobial protection is limited to the glass product itself, and neither Corning nor Diebold makes any direct or implied health claims about the antimicrobial properties of the product.

About Corning Incorporated

Corning (www.corning.com) is one of the world’s leading innovators in materials science. For more than 160 years, Corning has applied its unparalleled expertise in specialty glass, ceramics and optical physics to develop products that have created new industries and transformed people’s lives. Corning succeeds through sustained investment in R&D, a unique combination of material and process innovation, and close collaboration with customers to solve tough technology challenges. Corning’s businesses and markets are constantly evolving. Today, Corning’s products enable diverse industries such as consumer electronics, telecommunications, transportation and life sciences. They include damage-resistant cover glass for smartphones and tablets; precision glass for advanced displays; optical fiber, wireless technologies and connectivity solutions for high-speed communications networks; trusted products that accelerate drug discovery and manufacturing; and emissions-control products for cars, trucks and off-road vehicles.

About Diebold

Diebold, Incorporated (NYSE: DBD) is a global leader in providing innovative self-service technology, security systems and related services. Diebold has approximately 16,000 employees worldwide and is headquartered near Canton, Ohio, USA. Visit Diebold at www.diebold.com or on Twitter: http://twitter.com/DieboldInc.

Health Care

Emery Oleochemicals Marks Key Milestone with Site Pre-commissioning Activities of World’s First “Renewable and Recyclable Polyol” Plant

admin

Initiation of US$50mil expansion set to advance innovations in sustainable polyurethanes and drive sustainability opportunities with “closed-loop” processing

CINCINNATI, Ohio, December 30, 2014 /PRNewswire/ — Emery Oleochemicals, a world leader in natural-based chemicals announced that construction activities of its new technologically advanced bio-polyol plant located in Cincinnati, Ohio has reached mechanical completion. The plant will further strengthen Emery Oleochemicals’ ability to provide wide range of Eco-Friendly Polyoyls products and customer service.

With the initiation of pre-commissioning activities and site operational verification, startup of the first phase of the US$50mil investment marks a key milestone in the expansion project designed to boost capacity and technical capabilities in the manufacturing of performance bio-based polyols for the automotive, furniture and bedding and major appliances industries.

Announced in 2012, the project will reach initial production goals by the end of the year specifically in the area of renewable-based polyols, using Emery Oleochemicals’ proprietary ozonolysis technology.

“Once the commercial operation of the first phase begins, the bio-polyol plant will demonstrate unique capabilities of renewable-based polyols that can deliver on both performance and cost,” said Jay Taylor, Senior Vice President, Chief Manufacturing Officer and Regional Managing Director, North America.

The second phase adjoins in this same manufacturing complex and is in its final building stage with civil and structural installation at various process units nearing completion. This state-of-the-art site is dedicated to the production of recyclable polyols, bringing to life Emery Oleochemicals’ “closed-loop” processing value proposition and marks the successful integration of award-winning INFIGREEN® technology acquired in 2012.

“Supported by over 100 workers and external consultants, we have done an excellent job in constructing what will be the world’s first commercial plant offering both renewable and recyclable polyols for polyurethanes. Surpassing over 1.6 million man hours without a lost time accident, the facility already allows potential customers to explore opportunities in which our products can be economically integrated into their product development goals as we also embark on pre-marketing activities,” added Taylor.

When full facility commissioning completes in Q2 2015, the Cinccinati site will additionally produce solutions for Emery Oleochemicals’ Agro Green, Bio-Lubricants and Green Polymer Additives businesses, therefore providing natural-based solutions in market segments such as agriculture, lubricants, oilfield, packaging, toys and other high-growth industries.

“As we reach this first critical milestone, we are very pleased with the team’s effort in delivering on a international-standard project while meeting the highest specifications of safety, quality of construction, and maintaining costs and scheduling commitments,” said Dr.Kongkrapan Intarajang, Group Chief Executive Officer, during a recent site visit.

“This project is a testament to our global strategy of growing our innovation capabilities in providing natural-based specialty chemical solutions. Combined with our enhanced technical development centre here in Cincinnati, we are poised to drive the innovation and sustainability agenda in bio-polyols. By positioning ourselves in the radar of automotive industry players, we aim to be a preferred partner to deliver quality solutions the global marketplace have come to expect from Emery Oleochemicals,” Dr. Intarajang added.

The company’s Eco-Friendly Polyols business unit aims to demonstrate opportunities for the automotive industry to meet performance and sustainability goals through a specially designed Concept Car called “CASP” (Concepts for Advanced Sustainability in Polyurethanes) at the upcoming North American International Auto Show 2015. Featuring automotive components and materials made from both renewable and recycled polyurethane foam, CASP is a distinctive first for a chemicals manufacturing company. CASP will demonstrate Emery Oleochemicals’ proprietary technology in which recovered foam scrap materials were chemically processed and turned into recycled polyol are used in the production of polyurethane foams. This will be on display in Cobo Hall, Cobo Center Detroit, Michigan from January 12th to 25th 2015.

About Emery Oleochemicals Group

A leading producer of natural-based chemicals made predominantly from natural oils and fats such as plant-based oil and tallow. We offer an extensive product portfolio, including renewable solutions for the Agro Green, Bio-Lubricants, Eco-Friendly Polyols, Green Polymer Additives, Home & Personal Wellness and OleoBasics markets. With revenue of US$1billion (2013), the company is headquartered in Malaysia with manufacturing plants spanning three continents – Asia Pacific, North America, and Europe. Emery Oleochemicals’ global operations are backed by a diverse workforce and an extensive distribution network covering over 50 countries worldwide.

For more information, please log on to www.emeryoleo.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/emery-oleochemicals-marks-key-milestone-with-site-pre-commissioning-activities-of-worlds-first-renewable-and-recyclable-polyol-plant-300014430.html

Health Care

Emery Oleochemicals’ Natural-based Solutions Designed to Safeguard the Future of Bees, Credited as ‘Non-toxic’

admin

CINCINNATI, Ohio, December 5, 2014 /PRNewswire/ — Various organisations around the world have placed great importance to ensure the sustainability of the food supply, which is reliant on pollinators such as honey bees, native bees, birds, bats and butterflies. These pollinators, particularly honey bee colonies, are affected as a result of four primary factors: poor nutrition, pathogens, parasites [varroa mites] and insecticides. In recognising the need for non-toxic and renewable-based products to safe-guard against the population decline of honey bees, Emery Oleochemicals, through a recently completed evaluation by an independent testing laboratory, has concluded that the range of fatty acids offered as part of the EMERION™ 7000 and 8000 series are non-toxic and pollinator-friendly.

The EMERION™ 7000 product in itself, currently available in the marketplace, consists of ammonium nonanoate; and has been designed to complement the current portfolio of non-selective herbicide and bioactive ingredients suitable for all crops and home and garden. Also tested was the EMERION™ 8300, which offers natural-based properties through a custom blend of C8, C9 and C10 fatty acids in clay. Further formulations are currently being undertaken for this product.

The evaluation was conducted by an independent and AAALAC (Association for Assessment and Accreditation of Laboratory Animal Care) accredited contract research facility focused on the professional assessment of products in the areas of mammalian and environmental toxicology, animal health, entomology, analytical services, and in vitro studies. The objective of the study was to ascertain the acute contact toxicity of the Emery Oleochemicals’ products when administered to honey bees.

In this test, the colony of Apis mellifera – worker honey bee, that is disease and pest free with no previous pesticide exposure, were observed for a total of 48 hours. The species, selected as part of regulatory guidelines for these types of studies, were carefully tested by experts to ensure there are no significant differences in mortality between the test substance group and the control in bees. Tests results showed that toxicity to be greater than 100 microgram a.i./bee and therefore, non-toxic to honey bees.

Species such as honey bees are said by researchers to be responsible for pollinating around one-third of the world’s crop production. In US alone, honey bees are reported to add more than USD$15bn in value to local agriculture and over USD$29bn annually in Europe. With increasing concern from farmers and the community alike on the collapse of the bee population, industry players are hard pressed to look at alternatives and improvements to current farming practices.

The timely introduction of these new products precedes Emery Oleochemicals’ next effort which is to determine the efficacy of the EMERION™ fatty acid blend in controlling the varroa mite. In addition, the company plans to demonstrate that its natural-based solutions ensure the safety of consumers and the environment – addressing the rising global concern of food production security, sustainability of crop growth and the impact of farming practices on the environment.

With a strong portfolio in renewable agricultural solutions, Emery Oleochemicals’ Agro Green business unit offers a wide range of products with applications ranging from weed and crop management, surfactants, abiotic stress control, solvents, de-suckering agents and herbicides. Currently its trademark portfolio includes EMERION™, EMERLIFE™, EMTROL™ and EMEREEN™ with solutions that are additionally OMRI® certified, providing the marketplace with alternative, natural-based solutions that focuses on the need for environmentally responsible agrochemical formulations. Its product innovations provide continued advancements in agricultural productivity, meeting today’s evolving farming practices towards sustainable living.

About Emery Oleochemicals

Emery Oleochemicals is a leading producer of natural-based chemicals made predominantly from natural oils and fats such as plant-based oil and tallow. We offer an extensive product portfolio, including renewable solutions for the Agro Green, Bio-Lubricants, Eco-Friendly Polyols, Green Polymer Additives, Home & Personal Wellness and OleoBasics markets.

With revenue of US$1billion (2013), the company is headquartered in Malaysia with manufacturing plants spanning three continents – Asia Pacific, North America, and Europe. Emery Oleochemicals’ global operations are backed by a diverse workforce and an extensive distribution network covering over 50 countries worldwide.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/emery-oleochemicals-natural-based-solutions-designed-to-safeguard-the-future-of-bees-credited-as-non-toxic-300005412.html